Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings

Patrick J O'Connor, Richard J Gray, Michael V Maciosek, Kelly M Fillbrandt, Terese A DeFor, Charles M Alexander, Thomas W Weiss, Steven M Teutsch, Patrick J O'Connor, Richard J Gray, Michael V Maciosek, Kelly M Fillbrandt, Terese A DeFor, Charles M Alexander, Thomas W Weiss, Steven M Teutsch

Abstract

Introduction: Therapy with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, has proven to be effective in the treatment of lipid disorders. However, statin therapy continues to be underused, even though statins are a relatively safe and well-tolerated class of agents. In this study, we assessed trends in lipid control in patients with heart disease who receive most of their health care in primary care clinics. The objective was to determine whether systems of care implemented within a large medical group are associated with improved treatment and control of dyslipidemia in a high-risk group of coronary heart disease patients.

Methods: All adults with heart disease in a Minnesota medical group (N = 2947) were identified using diagnosis and procedure codes related to coronary heart disease (sensitivity = 0.85; positive predictive value = 0.89) in 1996. Study subjects were observed from 1995 to 1998. Subjects had a baseline and follow-up test for low-density lipoprotein cholesterol and high-density lipoprotein cholesterol. Changes between baseline and follow-up measurements and trends in the use of statins and other lipid-active agents among the study subjects were analyzed.

Results: Among 1388 subjects with two or more eligible lipid measurements, mean low-density lipoprotein cholesterol improved from 137.6 mg/dL to 111.0 mg/dL (P < .001), and mean high-density lipoprotein cholesterol improved from 42.3 mg/dL to 46.3 mg/dL (P < .001). The percentage of patients with low-density lipoprotein cholesterol < or = 100 mg/dL rose from 12.5% to 39.8% (P < .001), and the percentage with high-density lipoprotein cholesterol > or = 40 mg/dL rose from 52.5% to 67.6% (P < .001). In multivariate models, statin use was identified as the main factor that contributed to the improvement in low-density lipoprotein cholesterol (P < .001). Men had greater decreases in low-density lipoprotein cholesterol than women after adjusting for other variables (P < .001). Statin use rose from 24.3% at baseline to 69.6% at follow-up. The statin discontinuation rate was 8.3% for baseline statin users and 12.2% for subjects who used statins at any time during the study period.

Conclusion: Investment in better heart disease care for patients in primary care clinics led to major improvement in lipid control over 30 months, primarily due to increased statin use. Improvements in low-density lipoprotein cholesterol and high-density lipoprotein cholesterol were sufficient to substantially reduce risk of subsequent major cardiovascular events.

References

    1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344(8934):1383–1389.
    1. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001–1009.
    1. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study. Circulation. 2004;110:386–391.
    1. Larosa JC, Grundy MD, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med. 2005;352:1–11.
    1. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation. 2000;102(16):1893–1900.
    1. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239.
    1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.
    1. Arnett DK, McGovern PG, Jacobs DR, Shahar E, Duval S, Blackburn H, et al. Fifteen-year trends in cardiovascular risk factors (1980-1982 through 1995-1997): The Minnesota heart survey. Am J Epidemiol. 2002 Nov 15;156(10):929–935.
    1. Sueta CA, Chowdhury M, Boccuzzi SJ, Smith SC, Jr, Alexander CM, Londhe A, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999;83(9):1303–1307.
    1. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459–467.
    1. Institute for Clinical Systems Improvement. Health care guideline: treatment of lipid disorder in adults. Bloomington (MN): Institute for Clinical Systems Improvement; Nov, 2000.
    1. Carleton RA, Dwyer J, Finberg L, Flora J, Goodman DS, Grundy SM, et al. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. A statement from the National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health. Circulation. 1991;83:2154–2232.
    1. O'Connor P, Rush W, Pronk N, Cherney L. Identifying diabetes mellitus or heart disease among health maintenance organization members: sensitivity, specificity, predictive value, and cost of survey and database methods. Am J Manag Care. 1998;4(3):335–342.
    1. McGowan MW, Artiss JD, Strandbergh DR, Zak B. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem. 1983;29(3):538–542.
    1. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem. 1982;28(6):1379–1388.
    1. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20(4):470–475.
    1. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
    1. Dilman DA. Mail and telephone surveys: the total design method. Indianapolis (IN): John Wiley & Sons, Inc; 1978.
    1. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, et al. Discontinuation of antihyperlipidemic drugs — do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332(17):1125–1131.
    1. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455–461.
    1. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462–467.
    1. Sperl-Hillen J, O'Connor PJ, Carlson RR, Lawson TB, Halstenson C, Crowson T, et al. Improving diabetes care in a large health care system: an enhanced primary care approach. Jt Comm J Qual Improv. 2000;26(11):615–622.
    1. O'Connor PJ, Rush WA, Rardin KA, Isham G. Are HMO members willing to engage in two-way communication to improve health? HMO Pract. 1996;10(1):17–19.
    1. O'Connor PJ, Rush WA, Peterson J, Morben P, Cherney L, Keogh C, et al. Continuous quality improvement can improve glycemic control for HMO patients with diabetes. Arch Fam Med. 1996;5(9):502–506.
    1. O'Connor PJ, Desai J, Rush WA, Cherney LM, Solberg LI, Bishop DB. Is having a regular provider of diabetes care related to intensity of care and glycemic control? J Fam Pract. 1998;47(4):290–297.
    1. O'Connor P, Pronk N, Tan A, Rush W, Gray R. Does professional advice influence aspirin use to prevent heart disease in an HMO population? Eff Clin Pract. 1998;1(1):26–32.
    1. Ayanian JZ, Landrum MB, McNeil BJ. Use of cholesterol-lowering therapy by elderly adults after myocardial infarction. Arch Intern Med. 2002;162(9):1013–1019.
    1. Yarzebski J, Spencer F, Goldberg RJ, Lessard D, Gore JM. Temporal trends (1986-1997) in cholesterol level assessment and management practices in patients with acute myocardial infarction: a population-based perspective. Arch Intern Med. 2001;161(12):1521–1528.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir